Invesco
ODT

Invesco’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Invesco’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-254,463
Closed -$3.42M – 3856
2020
Q3 		$3.42M Sell
254,463
-20,641
-8% -$585K ﹤0.01% 2207
2020
Q2 		$11.6M Sell
275,104
-3,674
-1% -$119K ﹤0.01% 1555
2020
Q1 		$7.7M Buy
278,778
+21,423
+8% +$625K ﹤0.01% 1653
2019
Q4 		$8.35M Sell
257,355
-2,434
-0.9% -$75.4K ﹤0.01% 1874
2019
Q3 		$6.76M Sell
259,789
-127,762
-33% -$4.28M ﹤0.01% 1960
2019
Q2 		$14.2M Buy
387,551
+5
+0% +$120 ﹤0.01% 1596
2019
Q1 		$8.57M Sell
387,546
-365
-0.1% -$6.38K ﹤0.01% 1667
2018
Q4 		$5.46M Sell
387,911
-2,430
-0.6% -$37.8K ﹤0.01% 1885
2018
Q3 		$7.58M Sell
390,341
-22,654
-5% -$462K ﹤0.01% 1890
2018
Q2 		$9.12M Buy
412,995
+28
+0% +$652 ﹤0.01% 1733
2018
Q1 		$8.75M Sell
412,967
-3,700
-0.9% -$87.3K ﹤0.01% 1631
2017
Q4 		$10.4M Buy
+416,667
New +$9.84M ﹤0.01% 1549

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Invesco's ODT Position: Q4 2020 in Review

Invesco sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2020, closing a stake of 254,463 shares — an estimated $3.42M sold.

Invesco first reported a position in ODT in Q4 2017 and held it in 12 quarters. The position peaked at $14.2M in Q2 2019. 94 funds tracked by Wall St. Rank hold ODT as of Q4 2020.

  • Invesco reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Invesco sold 254,463 Odonate Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $3.42M.
  • Invesco first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2017 and held it in 12 quarters.
  • Invesco's Odonate Therapeutics, Inc. Common Stock position peaked at $14.2M in Q2 2019.
  • 94 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Invesco's 13F filing for Q4 2020, filed 16 Feb 2021.